Siglecs: targets for immune regulation and cancer therapy

Siglecs (sialic acid-binding immunoglobulin-type lectins) are receptors predominantly located on the surface of hematopoietic cells. Recent publications highlight the important roles Siglecs play in tumor immunosurveillance making them attractive anti-cancer drug targets. Inhibitory receptors Siglec-7 and Siglec-9 are expressed on NK cells and recognize tumor-associated sialosides (1,2). Also, Siglec-15 (Catalog # 9227-SL) was identified as an immune suppressor by engaging an unknown receptor on T cells. Similar to PD-L1/PD-1 immune checkpoint blockade, Siglec-15 may be a potential target for cancer immunotherapy (3).

Siglecs interact with an array of linkage-specific sialic acids on a glycan structure expressed on host cells, as well as pathogens. So far, there are 15 different human and 9 murine Siglecs. Each type of Siglec generally recognizes a particular set of sialylated glycan containing differently linked sialic acid molecules (4,5). On the cytoplasmic side, most Siglecs have immune receptor tyrosine-based inhibition motifs (ITIM), which initiate signaling cascades resulting in downregulation of proinflammatory responses.

R&D Systems provides you with the widest selection of high-quality, bioactive Siglecs on the market. Can’t find what you are looking for? The R&D Systems Custom Protein Development Team can work with you to create a customized protein solution to meet your specific research needs.

View Larger Image	View Larger Image	View Larger Image
Recombinant Cynomolgus Monkey Siglec‑2/CD22 Fc Chimera (Catalog # 10031-SL) supports the adhesion of human red blood cells. The ED50 for this effect is 0.07-0.42 ug/mL.	Recombinant Human Siglec-15 Fc Chimera (Catalog # 9227-SL) inhibits anti-CD3 antibody induced IFN-gamma secretion by human T cells. The ED50 for this effect is 1-10 μg/mL.	2 μg/lane of Recombinant Mouse Siglec‑F His-tag (Catalog # 10171-SF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 59-68 kDa.

References:

1. Jandus, C. et al. (2014) J. Clin. Investig. 124:1810.

2. Stanczak, M.A. et al. (2018) J. Clin. Investig. 128:4912.

3. Wang, J. et al. (2019) Nat. Med. 25:656.

4. Bornhöfft, K.F. et al. (2018) Dev. Comp. Immunol. 86:219.

5. Zhou, J.Y. et al. (2018) Trends Immunol. 39:523.

View other Immune-checkpoint blockade targets

• B7/CD28 Family

  Some of the most targeted checkpoint proteins

• Butyrophilins

  Products for Butyrophilin-related Research

• AMIGOs

  New Data: AMIGOs as T Cell Suppressors

• LILRA/B Receptors

  Checkpoint Targets with Novel Ligands

• VSIG

  IgG Superfamily Members: Data Supports Their Potential as Immunotherapeutic Drug Targets

• VSTM

  New B7-like immune checkpoint targets

• CEACAMs

  Adhesion Molecules as Novel Targets for Cancer Therapies

• SIRPs

  Paired receptors with either activating or inhibitory signals.

Related Pathways

T Cell Co-Signaling Pathway: Ligand-Receptor Interactions

Mechanisms of Regulatory T Cell-Mediated Suppression

Other immune-checkpoint blockade resources:

• Immune Checkpoint

• Immune Checkpoint Blockade: Immune Checkpoint Molecule Expression

• Immune Checkpoint Blockade: Immune Cell Phenotyping and Isolation

• Immune Checkpoint Blockade: T Cell Responses

• VSIG8 Poster: Co-inhibitory Immune Checkpoint Molecule

• Webinar Short: B7-related Butryophilins as Immune Modulators

• Immunotherapy

• A Role for VSIG-3/VISTA Signaling in Acquired Resistance to Anti-PD-1 Therapy?

All proteins from R&D Systems

• Recombinant Proteins

• Good Manufacturing Practices (GMP)-grade Proteins

• Custom Protein Services